Innate Pharma (IPHA) Short Interest Ratio & Short Volume $2.00 +0.04 (+1.81%) Closing price 04/23/2025 03:58 PM EasternExtended Trading$1.96 -0.04 (-1.78%) As of 04/23/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Innate Pharma Short Interest DataInnate Pharma (IPHA) has a short interest of 407,300 shares, representing 0.71% of the float (the number of shares available for trading by the public). This marks a -2.35% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.8, indicating that it would take 1.8 days of the average trading volume of 183,480 shares to cover all short positions.Current Short Interest407,300 sharesPrevious Short Interest417,100 sharesChange Vs. Previous Month-2.35%Dollar Volume Sold Short$724,994.00Short Interest Ratio1.8 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares83,830,000 sharesShort Percent of Float0.71%Today's Trading Volume61,219 sharesAverage Trading Volume183,480 sharesToday's Volume Vs. Average33% Short Selling Innate Pharma? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIPHA Short Interest Over TimeIPHA Days to Cover Over TimeIPHA Percentage of Float Shorted Over Time Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2025407,300 shares $724,994.00 -2.4%0.7%1.8 $1.78 3/15/2025417,100 shares $812,927.90 -9.6%0.7%1.8 $1.95 2/28/2025461,400 shares $978,168.00 +199.2%0.8%0.7 $2.12 2/15/2025154,200 shares $299,148.00 +1.1%0.3%0.2 $1.94 1/31/2025152,500 shares $279,075.00 +44.7%N/A0.3 $1.83 1/15/2025105,400 shares $179,180.00 +4.4%N/A0.2 $1.70 12/31/2024101,000 shares $185,840.00 -88.9%N/A0.2 $1.84 12/15/2024909,800 shares $2.75 million +1,344.1%N/A2 $3.02 11/30/202463,000 shares $97,020.00 -1.1%N/A0.3 $1.54 11/15/202463,700 shares $91,728.00 -2.3%N/A6.2 $1.44 Get the Latest News and Ratings for IPHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 10/31/202465,200 shares $123,293.20 +10.9%N/A7.8 $1.89 10/15/202458,800 shares $119,364.00 -18.1%N/A7.4 $2.03 9/30/202471,800 shares $164,422.00 +20.3%N/A10 $2.29 9/15/202459,700 shares $134,922.00 -8.3%N/A9 $2.26 8/31/202465,100 shares $149,404.50 -2.5%N/A9.3 $2.30 8/15/202466,800 shares $150,300.00 +3.6%N/A8.1 $2.25 7/31/202464,500 shares $138,352.50 -11.5%N/A7.8 $2.15 7/15/202472,900 shares $154,548.00 +5.2%N/A9.1 $2.12 6/30/202469,300 shares $134,442.00 -4.9%N/A7.7 $1.94 6/15/202472,900 shares $171,315.00 +4.1%N/A7 $2.35 5/31/202470,000 shares $191,800.00 -0.3%N/A6.7 $2.74 5/15/202470,200 shares $175,942.26 -11.3%N/A7.2 $2.51 4/30/202479,100 shares $182,721.00 -2.7%N/A8.8 $2.31 4/15/202481,300 shares $196,746.00 +5.7%N/A7.8 $2.42 3/31/202476,900 shares $221,472.00 -13.7%N/A7.7 $2.88 3/15/202489,100 shares $217,404.00 +13.7%N/A7.6 $2.44 2/29/202478,400 shares $205,408.00 -4.9%N/A4.1 $2.62 2/15/202482,400 shares $212,592.00 +8.4%N/A4.7 $2.58 1/31/202476,000 shares $203,680.00 -0.9%N/A4 $2.68 1/15/202476,700 shares $214,760.00 -8.9%N/A3.7 $2.80 12/31/202384,200 shares $235,760.00 +55.9%N/A3.9 $2.80 12/15/202354,000 shares $130,140.00 -5.9%N/A2.6 $2.41 11/30/202357,400 shares $137,760.00 -4.3%N/A4.3 $2.40 11/15/202360,000 shares $147,600.00 -6.0%N/A4.2 $2.46 10/31/202363,800 shares $151,844.00 +11.5%N/A4.4 $2.38 10/15/202357,200 shares $132,418.00 -8.5%N/A5 $2.32 9/30/202362,500 shares $158,125.00 -3.4%N/A6 $2.53 9/15/202364,700 shares $192,159.00 -1.5%N/A6.7 $2.97 8/31/202365,700 shares $191,324.97 -8.1%N/A5.2 $2.91 8/15/202371,500 shares $206,635.00 -3.8%N/A6.1 $2.89What President Trump’s Executive Order 14154 means for your money (Ad)Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.But because of the massive changes impacting U.S. stocks, Tilson has agreed to publish his latest fi 7/31/202374,300 shares $218,442.00 -1.9%N/A6.8 $2.94 7/15/202375,700 shares $244,511.00 -3.8%N/A6.4 $3.23 6/30/202378,700 shares $242,002.50 +20.0%N/A6.1 $3.08 6/15/202365,600 shares $213,856.00 +9.7%N/A4 $3.26 5/31/202359,800 shares $175,812.00 -4.3%N/A3.8 $2.94 5/15/202362,500 shares $186,875.00 No ChangeN/A3.6 $2.99 10/31/2022147,600 shares $317,340.00 +12.8%N/A12.9 $2.15 10/15/2022130,900 shares $261,800.00 +15.5%N/A12.5 $2.00 9/30/2022113,300 shares $226,600.00 +1.3%N/A12.7 $2.00 9/15/2022111,900 shares $284,226.00 +2.3%N/A13.3 $2.54 8/31/2022109,400 shares $293,192.00 +0.2%N/A6.4 $2.68 8/15/2022109,200 shares $321,048.00 -10.1%N/A5.9 $2.94 7/31/2022121,500 shares $388,787.85 -3.6%N/A6.1 $3.20 7/15/2022126,000 shares $347,760.00 +0.3%N/A4.9 $2.76 6/30/2022125,600 shares $339,120.00 +3.9%N/A4.8 $2.70 6/15/2022120,900 shares $305,877.00 +1.9%N/A4.6 $2.53 5/31/2022118,700 shares $315,742.00 -13.6%N/A6.2 $2.66 5/15/2022137,300 shares $394,051.00 +8.0%N/A6.7 $2.87 4/30/2022127,100 shares $364,777.00 -9.3%N/A5.7 $2.87 4/15/2022140,100 shares $438,513.00 +4.0%N/A6 $3.13 3/31/2022134,700 shares $452,592.00 +105.0%N/A5.3 $3.36 3/15/202265,700 shares $207,612.00 +13.9%N/A1.6 $3.16 2/28/202257,700 shares $196,757.00 -2.5%N/A1 $3.41 2/15/202259,200 shares $219,632.00 -15.6%N/A0.9 $3.71 1/31/202270,100 shares $265,679.00 -15.3%N/A1 $3.79 1/15/202282,800 shares $375,084.00 -22.3%N/A1.1 $4.53 12/31/2021106,600 shares $486,096.00 +247.2%N/A1.3 $4.56 12/15/202130,700 shares $158,105.00 +0.3%N/A0.3 $5.15 11/30/202130,600 shares $151,776.00 -39.8%N/A0 $4.96 11/15/202150,800 shares $263,652.00 +195.4%N/A0 $5.19 10/29/202117,200 shares $99,760.00 +18.6%N/A0 $5.80 10/15/202114,500 shares $85,115.00 -89.5%N/A0 $5.87 9/30/2021137,800 shares $850,226.00 +79.7%N/A0.1 $6.17 9/15/202176,700 shares $427,986.00 +2,456.7%N/A0 $5.58 8/31/20213,000 shares $10,920.00 -45.5%N/A0 $3.64 8/13/20215,500 shares $18,700.00 -35.3%N/A0.3 $3.40 7/30/20218,500 shares $28,220.00 -33.6%N/A0.5 $3.32 7/15/202112,800 shares $41,472.00 +100.0%N/A0.7 $3.24 6/30/20216,400 shares $21,056.00 -61.0%N/A0.4 $3.29 6/15/202116,400 shares $65,764.00 +1,161.5%N/A1.1 $4.01 5/28/20211,300 shares $5,083.00 +225.0%N/A0.1 $3.91 5/14/2021400 shares $1,580.00 -81.8%N/A0 $3.95 4/30/20212,200 shares $9,416.00 -29.0%N/A0.1 $4.28 4/15/20213,100 shares $13,578.00 -55.7%N/A0 $4.38 3/31/20217,000 shares $30,030.00 -6.7%N/A0.2 $4.29 3/15/20217,500 shares $34,275.00 +53.1%N/A0.2 $4.57 2/26/20214,900 shares $21,658.00 -27.9%N/A0.1 $4.42 2/12/20216,800 shares $30,804.00 +385.7%N/A0.2 $4.53 1/29/20211,400 shares $5,740.00 -74.1%N/A0 $4.10 1/15/20215,400 shares $24,516.00 -77.2%N/A0.2 $4.54What President Trump’s Executive Order 14154 means for your money (Ad)Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.But because of the massive changes impacting U.S. stocks, Tilson has agreed to publish his latest fi 12/31/202023,700 shares $102,147.00 -52.5%N/A0.9 $4.31 12/15/202049,900 shares $219,061.00 +91.2%N/A2.5 $4.39 11/30/202026,100 shares $145,116.00 -7.1%N/A1.5 $5.56 11/15/202028,100 shares $133,475.00 -23.2%N/A1.6 $4.75 10/30/202036,600 shares $146,217.00 +21.6%N/A2.5 $4.00 10/15/202030,100 shares $121,002.00 +32.6%N/A2.5 $4.02 9/30/202022,700 shares $87,168.00 -22.5%N/A2.2 $3.84 9/15/202029,300 shares $127,455.00 +70.4%N/A2.9 $4.35 8/31/202017,200 shares $106,812.00 -5.5%N/A2.2 $6.21 8/14/202018,200 shares $119,210.00 -40.9%N/A2.3 $6.55 7/31/202030,800 shares $187,205.48 +76.0%N/A3.3 $6.08 7/15/202017,500 shares $105,175.00 +25.9%N/A2.1 $6.01 6/30/202013,900 shares $88,404.00 -0.7%N/A1.7 $6.36 6/15/202014,000 shares $87,780.00 -23.1%N/A1.4 $6.27 5/29/202018,200 shares $121,030.00 -59.4%N/A1.3 $6.65 5/15/202044,800 shares $300,160.00 +44.5%N/A2.7 $6.70 4/30/202031,000 shares $235,600.00 -13.9%N/A1.9 $7.60 IPHA Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 407,300 shares of IPHA short. 0.71% of Innate Pharma's shares are currently sold short. Learn More on Innate Pharma's current short interest. What is a good short interest ratio for Innate Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 2.0. Learn More on Innate Pharma's short interest ratio. What is a good short interest percentage for Innate Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.71% of Innate Pharma's floating shares are currently sold short. Is Innate Pharma's short interest increasing or decreasing? Innate Pharma saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 407,300 shares, a decline of 2.3% from the previous total of 417,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Innate Pharma's short interest compare to its competitors? 0.71% of Innate Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Innate Pharma: AnaptysBio, Inc. (53.19%), Xeris Biopharma Holdings, Inc. (11.98%), Arbutus Biopharma Co. (5.41%), ChromaDex Co. (4.29%), Arvinas, Inc. (9.80%), KalVista Pharmaceuticals, Inc. (13.25%), Trevi Therapeutics, Inc. (9.46%), Keros Therapeutics, Inc. (12.97%), Pharming Group (0.00%), Valneva SE (0.02%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies AnaptysBio Short Interest Xeris Biopharma Short Interest Arbutus Biopharma Short Interest ChromaDex Short Interest Arvinas Short Interest KalVista Pharmaceuticals Short Interest Trevi Therapeutics Short Interest Keros Therapeutics Short Interest Pharming Group Short Interest Valneva Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IPHA) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPHA Stock Free IPHA Stock Alerts